S-peptid, qon zardobi
Kod:9061
| Kabi | S-peptid |
|---|
Tahlil ma'lumotlari
Tadqiqot usuli
- Elektrokimyoluminessent immunoanaliz (ECLIA)
- Kimyoluminessent immunoanaliz (CLIA)
Kutilayotgan natija topshirish vaqti
1 kun
Maxsus tayyorlik
- Do not consume alcohol during the 24 hours before the blood draw.
- Fast for at least 8 hours before collection; water is allowed.
- Avoid vigorous exercise and emotional stress for the 30 minutes preceding collection.
- Do not smoke during the 3 hours before the specimen is collected.
- High-dose biotin (vitamin B7) can interfere with immunoassays; stop biotin supplements for at least 72 hours before collection.
Qanday foydalanish
S-peptid, qon zardobi (bog‘lovchi peptid) endogen insulin sekretsiyasi va beta-hujayralar zaxirasini baholash uchun qo‘llanadi. U dastlabki murojaatda 1-toifa va 2-toifa diabetni farqlashni qo‘llab-quvvatlaydi, ayniqsa bolalar va yosh kattalarda, hamda 2-toifa diabetda maksimal og‘zaki terapiyaga qaramay glikemik nazorat yetarli bo‘lmaganda insulinoterapiyani qachon boshlash masalasida yordam beradi. Ketma-ket o‘lchovlar 1-toifa diabetda qolgan beta-hujayra funksiyasini kuzatish va orolchalar yoki oshqozon osti bezi transplantatsiyasidan keyin greft funksiyasini baholash uchun qo‘llanadi. Tahlil, shuningdek, endogen giperinsulinizmni baholashga va gumon qilingan insulinoma uchun diagnostik tekshiruvga hissa qo‘shadi.
Cheklovlar
S-peptid — proinsulinning tarkibida A va B zanjirlarini bog‘lab turuvchi peptid segment bo‘lib, proinsulin faol shaklga qayta ishlanganda insulin bilan ekuimolyar miqdorda ajraladi. Insulinga nisbatan, u jigar tomonidan first-pass (birinchi o‘tish) klirensiga sezilarli darajada uchramaydi; shu bois periferik S-peptid konsentratsiyasi oshqozon osti bezidan chiqadigan insulin ishlab chiqarishining ishonchliroq surrogat ko‘rsatkichi hisoblanadi. O‘lchovga ekzogen insulin yuborilishi ta’sir qilmaydi va u to‘g‘ridan-to‘g‘ri insulin tahlillariga nisbatan anti-insulin antitanachalaridan kamroq ta’sirlanadi. Klinik jihatdan, S-peptid autoimmun 1-toifa diabetga xos bo‘lgan mutlaq insulin yetishmovchiligini 2-toifa diabetda kuzatiladigan insulin rezistentligi bilan birga kechuvchi nisbiy insulin yetishmovchiligidan farqlashga yordam beradi. U 1-toifa diabet boshlanishida prognozga oid ma’lumot beradi va beta-hujayra funksiyasini vaqt davomida kuzatishga imkon beradi. Tahlil, shu jumladan ko‘p bezli endokrin neoplaziya sharoitida rivojlangan holatlar bilan birga, insulinomani baholashda endogen giperinsulinizmni hujjatlashtiradi va orolchalar transplantatsiyasidan keyin greft funksiyasini baholashda qo‘llanadi.
| O'lchov birligi | ng/mL | ||||
|---|---|---|---|---|---|
| Referens oraliq |
| ||||
| Ko'rsatmalar | Workup of symptomatic hyperglycemia suggestive of type 1 diabetes (polydipsia, polyuria, weight loss, polyphagia)., Assessment of suspected type 2 diabetes or impaired glucose tolerance in overweight or obese individuals presenting with hyperglycemic symptoms., Evaluation of chronic hyperglycemia in the setting of microvascular or macrovascular complications, including diabetic retinopathy, peripheral neuropathy, diabetic foot ulcers, chronic kidney disease, coronary artery disease, and hypertension., Differentiation between type 1 and type 2 diabetes, with emphasis on newly diagnosed children and young adults., Monitoring of therapy response and residual beta-cell function in established type 1 diabetes., Decision support for starting insulin in type 2 diabetes when glycemic targets are not met on maximal oral agents., Investigation of fasting hypoglycemia due to endogenous hyperinsulinism, including suspected insulinoma with adrenergic and neuroglycopenic manifestations. |
Natija og'ishlarining mumkin sabablari
Oshgan daraja
- chronic hepatitis
- cirrhosis
Pasaygan daraja
- biotin supplementation (high dose)
Namunangiz talablari
| Namunangiz | Zardob |
|---|---|
| Container | Oltin/yo'lbars qopqoqli probirka (SST, gel ajratgich) |
| Hajm | 1 mL (min 0.7 mL) |
| Saqlash tayyorlik | Xona harorati, Sovutilgan, Muzlatilgan |
References
Chernecky C. C., Berger B. J. Laboratory Tests and Diagnostic Procedures. 5th ed. Saunders Elsevier; 2008.
Handelsman Y, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus: comprehensive care plan. Endocr Pract. 2011;17(Suppl 2):1–53.
Palmer J P, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21–22 October 2001. Diabetes. 2004;53(1):250–64.
Ryan E A, Paty B W, Senior P A, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54(7):2060–9.
Saisho Y, Kou K, Tanaka K, et al. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J. 2011;58(4):315–22.